Publication:
Nucleic acid recognition and antiviral activity of 1,4-substituted terphenyl compounds mimicking all faces of the HIV-1 Rev protein positively-charged α-helix

dc.contributor.authorMedina-Trillo, Cristina
dc.contributor.authorSedgwick, Daniel M
dc.contributor.authorHerrera, Lidia
dc.contributor.authorBeltran, Manuela
dc.contributor.authorMoreno, Ángela
dc.contributor.authorBarrio, Pablo
dc.contributor.authorBedoya, Luis M
dc.contributor.authorAlcamí, José
dc.contributor.authorFustero, Santos
dc.contributor.authorGallego, José
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderGeneralitat Valenciana (España)
dc.contributor.funderRed de Investigación Cooperativa en Investigación en Sida (España)
dc.date.accessioned2020-05-06T08:33:02Z
dc.date.available2020-05-06T08:33:02Z
dc.date.issued2020-04-28
dc.description.abstractSmall synthetic molecules mimicking the three-dimensional structure of α-helices may find applications as inhibitors of therapeutically relevant protein-protein and protein-nucleic acid interactions. However, the design and use of multi-facial helix mimetics remains in its infancy. Here we describe the synthesis and application of novel bilaterally substituted p-terphenyl compounds containing positively-charged aminoalkyl groups in relative 1,4 positions across the aromatic scaffold. These compounds were specifically designed to mimic all faces of the arginine-rich α-helix of the HIV-1 protein Rev, which forms deeply embedded RNA complexes and plays key roles in the virus replication cycle. Two of these molecules recognized the Rev site in the viral RNA and inhibited the formation of the RRE-Rev ribonucleoprotein complex, a currently unexploited target in HIV chemotherapy. Cellular assays revealed that the most active compounds blocked HIV-1 replication with little toxicity, and likely exerted this effect through a multi-target mechanism involving inhibition of viral LTR promoter-dependent transcription and Rev function. Further development of this scaffold may open new avenues for targeting nucleic acids and may complement current HIV therapies, none of which involve inhibitors interfering with the gene regulation processes of the virus.es_ES
dc.description.peerreviewedes_ES
dc.description.sponsorshipThis project was supported by Ministerio de Economía y Competitividad of Spain (Grants BFU2012–30770 and BFU2015–65103-R to J.G.; CTQ2013-43310 and CTQ2017-84249-P to S.F. and FIS PI16CIII/0034 to J.A.; and FPU15/01485 predoctoral fellowship to D.M.S.), Generalitat Valenciana of Spain (FPA/2015/014 and APOTIP/2016/A007 to J.G. and PROMETEOII/2014/073 to S.F.), the Spanish AIDS Research Network (RD16CIII/0002/0001-ISCIII–FEDER to J.A.), Universidad Católica de Valencia (2017-114-001 and 2018-114-001 to J.G.), and European AIDS Vaccine Initiative 2020 (ID 681137 to J.A.). The authors thank Ainhoa Sánchez for carrying out initial fluorescence anisotropy experiments, Ángel Cantero-Camacho for designing and testing the primers used to amplify LTRc, and Jerónimo Bravo and Antonio Pineda for facilitating access to ITC equipment. Plasmid pLTR(HTLV)-luc (pGL4.20-U3R) was kindly donated by Thomas Kress.es_ES
dc.format.number1es_ES
dc.format.page7190es_ES
dc.format.volume10es_ES
dc.identifier.citationSci Rep. 2020 Apr 28;10(1):7190.es_ES
dc.identifier.doi10.1038/s41598-020-64120-2es_ES
dc.identifier.e-issn2045-2322es_ES
dc.identifier.issn2045-2322es_ES
dc.identifier.journalScientific reportses_ES
dc.identifier.pubmedID32346097es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9917
dc.language.isoenges_ES
dc.publisherNature Publishing Group
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/BFU2012–30770es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/BFU2015–65103-Res_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/CTQ2013-43310es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/CTQ2017-84249-Pes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FIS PI16CIII/0034es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FPU15/01485es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/FPA/2015/014es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/APOTIP/2016/A007es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PROMETEOII/2014/073es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16CIII/0002/0001-ISCIII–FEDERes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/2017-114-001es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/2018-114-001es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/ID 681137es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-020-64120-2es_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.titleNucleic acid recognition and antiviral activity of 1,4-substituted terphenyl compounds mimicking all faces of the HIV-1 Rev protein positively-charged α-helixes_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication0afbdacd-48b9-407c-a9b6-3acdfccf86ec
relation.isAuthorOfPublication51e14860-d081-4f16-8e7c-8ed3c8c26722
relation.isAuthorOfPublication2fc55aca-54b0-411c-b170-c2149068a902
relation.isAuthorOfPublication.latestForDiscovery0afbdacd-48b9-407c-a9b6-3acdfccf86ec
relation.isFunderOfPublication77b2fc20-6311-4e46-98a7-83e46257b93b
relation.isFunderOfPublication842e6617-7822-4501-a927-7e8cedda4aa6
relation.isFunderOfPublication.latestForDiscovery77b2fc20-6311-4e46-98a7-83e46257b93b
relation.isPublisherOfPublication301fb00e-338e-4f8c-beaa-f9d8f4fefcc0
relation.isPublisherOfPublication.latestForDiscovery301fb00e-338e-4f8c-beaa-f9d8f4fefcc0

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
NucleicAcidRecognitionAnd_2020.pdf
Size:
2.11 MB
Format:
Adobe Portable Document Format
Description: